ReviewDiscover oncology2026
Research on the role and mechanism of FAT4 in the development and progression of tumor and non-tumor diseases.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FAT4 (FAT Atypical Cadherin 4), a member of the atypical cadherin family, represents the human ortholog of Drosophila Fat (Ft) and functions as a positive regulator of planar cell polarity in the Drosophila wing. It serves various functions during embryogenesis and adult tissue development, demonstrating calcium-dependent adhesive properties. FAT4 has been extensively studied regarding its physiological functions and tumor mechanisms, with numerous studies emphasizing its essential role in various biological processes. A systematic mechanistic analysis and review of its key functions across these various biological processes is lacking. FAT4, as a transmembrane adhesion receptor and tumor suppressor, is expressed in cells across multiple systems, diseases, and diverse cancer tissues. It performs essential functions in diverse biological processes by modulating cell proliferation, polarity, and the immune microenvironment through multiple signaling pathways. This review delineates the functions of FAT4 in tissue morphogenesis, autoimmune diseases, and malignancies. The inactivation of this gene (through mutation, methylation, and deletion) is closely associated with multisystem developmental anomalies, immune responses, and cancer progression, thereby establishing it as a potential prognostic marker and therapeutic target. This study aimed to enhance the understanding of FAT4 and evaluate its potential applications in clinical diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.